226 related articles for article (PubMed ID: 32197139)
1. Continued benefit demonstrated with BAY 81-8973 prophylaxis in previously treated children with severe haemophilia A: Interim analysis from the LEOPOLD Kids extension study.
Kenet G; Ljung R; Rusen L; Kerlin BA; Blanchette V; Saulytė Trakymienė S; Uscatescu V; Beckmann H; Tseneklidou-Stoeter D; Church N
Thromb Res; 2020 May; 189():96-101. PubMed ID: 32197139
[TBL] [Abstract][Full Text] [Related]
2. BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial.
Ljung R; Kenet G; Mancuso ME; Kaleva V; Rusen L; Tseneklidou-Stoeter D; Michaels LA; Shah A; Hong W; Maas Enriquez M;
Haemophilia; 2016 May; 22(3):354-60. PubMed ID: 26663410
[TBL] [Abstract][Full Text] [Related]
3. PROTECT VIII kids extension study: Long-term safety and efficacy of BAY 94-9027 (damoctocog alfa pegol) in children with severe haemophilia A.
Mancuso ME; Biss T; Fischer K; Maas Enriquez M; Steele M; Wang M; Tseneklidou-Stoeter D; Ahuja S; Kenet G
Haemophilia; 2021 May; 27(3):434-444. PubMed ID: 33724632
[TBL] [Abstract][Full Text] [Related]
4. PROTECT VIII Kids: BAY 94-9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A.
Santagostino E; Kenet G; Fischer K; Biss T; Ahuja S; Steele M
Haemophilia; 2020 May; 26(3):e55-e65. PubMed ID: 32212300
[TBL] [Abstract][Full Text] [Related]
5. BAY 94-9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results.
Lalezari S; Reding MT; Pabinger I; Holme PA; Negrier C; Chalasani P; Shin HJ; Wang M; Tseneklidou-Stoeter D; Maas Enriquez M
Haemophilia; 2019 Nov; 25(6):1011-1019. PubMed ID: 31621991
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme.
Oldenburg J; Windyga J; Hampton K; Lalezari S; Tseneklidou-Stoeter D; Beckmann H; Maas Enriquez M
Haemophilia; 2016 May; 22(3):349-53. PubMed ID: 26931631
[TBL] [Abstract][Full Text] [Related]
7. BAY 81-8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years.
Mahlangu J; Lopez Fernandez MF; Santagostino E; Lalezari S; Tseneklidou-Stoeter D; Beckmann H; Church N
Eur J Haematol; 2020 Jun; 104(6):594-601. PubMed ID: 32112434
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of BAY 81-8973, a full-length recombinant factor VIII: results from the LEOPOLD I trial.
Saxena K; Lalezari S; Oldenburg J; Tseneklidou-Stoeter D; Beckmann H; Yoon M; Maas Enriquez M
Haemophilia; 2016 Sep; 22(5):706-12. PubMed ID: 27339736
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial.
Yang R; Sun J; Zhao Y; Wang X; Wu D; Tseneklidou-Stoeter D; Wu J; Church N
Haemophilia; 2019 May; 25(3):e153-e158. PubMed ID: 30993836
[TBL] [Abstract][Full Text] [Related]
10. BAY 81-8973 (Octocog Alfa; Kovaltry
Keating GM
BioDrugs; 2016 Oct; 30(5):453-459. PubMed ID: 27577234
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII.
Reding MT; Ng HJ; Poulsen LH; Eyster ME; Pabinger I; Shin HJ; Walsch R; Lederman M; Wang M; Hardtke M; Michaels LA
J Thromb Haemost; 2017 Mar; 15(3):411-419. PubMed ID: 27992112
[TBL] [Abstract][Full Text] [Related]
12. A post hoc analysis of PROTECT VIII kids assessing long-term efficacy and safety of damoctocog alfa pegol in adolescents with severe haemophilia A.
Ahuja S; Biss T; Maas Enriquez M; Mancuso ME; Steele M; Kenet G
Eur J Haematol; 2024 May; 112(5):756-764. PubMed ID: 38193596
[TBL] [Abstract][Full Text] [Related]
13. Confirmed long-term safety and efficacy of prophylactic treatment with BAY 94-9027 in severe haemophilia A: final results of the PROTECT VIII extension study.
Reding MT; Pabinger I; Holme PA; Poulsen L; Negrier C; Chalasani P; Maas Enriquez M; Wang M; Meijer K; Mancuso ME; Lalezari S
Haemophilia; 2021 May; 27(3):e347-e356. PubMed ID: 33818853
[TBL] [Abstract][Full Text] [Related]
14. BAY 81-8973 Efficacy and Safety in Previously Untreated and Minimally Treated Children with Severe Hemophilia A: The LEOPOLD Kids Trial.
Ljung R; Chan AKC; Glosli H; Afonja O; Becker B; Tseneklidou-Stoeter D; Mancuso ME; Saulyte-Trakymiene S; Kenet G
Thromb Haemost; 2023 Jan; 123(1):27-39. PubMed ID: 36626898
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A.
Meunier S; Alamelu J; Ehrenforth S; Hanabusa H; Abdul Karim F; Kavakli K; Khodaie M; Staber J; Stasyshyn O; Yee DL; Rageliene L
Thromb Haemost; 2017 Aug; 117(9):1705-1713. PubMed ID: 28692108
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of prophylaxis with once-weekly BAY 79-4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients. A randomised, active-controlled, double-blind study.
Powell J; Martinowitz U; Windyga J; Di Minno G; Hellmann A; Pabinger I; Maas Enriquez M; Schwartz L; Ingerslev J;
Thromb Haemost; 2012 Nov; 108(5):913-22. PubMed ID: 23014711
[TBL] [Abstract][Full Text] [Related]
17. Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A.
Mullins ES; Stasyshyn O; Alvarez-Román MT; Osman D; Liesner R; Engl W; Sharkhawy M; Abbuehl BE
Haemophilia; 2017 Mar; 23(2):238-246. PubMed ID: 27891721
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial.
Lentz SR; Janic D; Kavakli K; Miljic P; Oldenburg J; C Ozelo M; Santagostino E; Suzuki T; Zupancic Šalek S; Korsholm L; Matytsina I; Tiede A
Haemophilia; 2018 Nov; 24(6):e391-e394. PubMed ID: 30402994
[TBL] [Abstract][Full Text] [Related]
19. BAY 81-8973 prophylaxis and pharmacokinetics in haemophilia A: Interim results from the TAURUS study.
Santoro C; Fuh B; Le PQ; Maes P; Berrueco R; Mingot-Castellano EM; von Mackensen S; Solms A; Wang M
Eur J Haematol; 2020 Aug; 105(2):164-172. PubMed ID: 32259334
[TBL] [Abstract][Full Text] [Related]
20. Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis.
Mancuso ME; Reding MT; Negrier C; Kerlin BA; Rangarajan S; Simpson ML
Thromb Haemost; 2021 Aug; 121(8):1079-1086. PubMed ID: 33296943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
